On 10th July 2017, NICE issued a new Technology Appraisal (TA) for bisphosphonates which links the recommendations for drug treatments to advice on fracture risk assessment outlined in their earlier guidance. The TA is not intended to provide treatment thresholds but offers recommendations on cost-effective use of bisphosphonates when using fracture risk assessment as described in their guideline www.nice.org.uk/
For the first time, these recommendations will apply to men as well as women.
The TA says that provided an individual meets the criteria for fracture risk assessment there should be no financial barrier to them receiving bisphosphonates if they have a fracture risk of at least 1% using FRAX or QFracture.…
Read more of this article

The National Osteoporosis Society launched ‘A Message to My Younger Self’ – an awareness campaign about keeping bones strong and healthy – on 12th April which runs through World Osteoporosis Day on 20 October.